Form 4: Sarepta Therapeutics CFO Exercises Stock Options, Sells Shares to Cover Taxes
SEC Form 4 Filing
Sarepta Therapeutics' Chief Financial Officer, Ian Michael Estepan, exercised stock options and sold a portion of the acquired shares to cover tax obligations on January 29, 2025.
Summary
- Ian Michael Estepan, the Chief Financial Officer of Sarepta Therapeutics, exercised stock options on January 29, 2025.
- He acquired 14,267 shares at an exercise price of $12 per share.
- He also acquired an additional 1,533 shares at the same exercise price.
- A total of 2,613 shares were sold at $117.51 per share to cover tax obligations related to the option exercise.
- Following these transactions, Mr. Estepan directly owns 46,883 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting standard executive compensation practices. It doesn't indicate any positive or negative sentiment about the company's performance.
Industry Context
This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the exercise of stock options granted to the CFO as part of his compensation package.
Comparison to Industry Standards
- Stock option exercises and subsequent sales to cover taxes are standard practice for executives in publicly traded companies.
- The exercise price of $12 and sale price of $117.51 are specific to Sarepta's stock performance and option grants.
- Similar transactions are regularly reported by executives at comparable biotech companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine executive compensation activity.
- The sale of shares to cover taxes may have a slight downward pressure on the stock price, but it is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 01/30/2016 | Date the stock options were granted. |
| 01/29/2025 | Date of stock option exercise and share sale. |
| 01/30/2025 | Expiration date of the stock options. |
| 01/31/2025 | Date the SEC Form 4 was signed. |
Keywords
stock options, insider trading, SEC Form 4, Sarepta Therapeutics, SRPT, equity, Ian Michael Estepan, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.